Sinovac Biotech, Ltd (SVA) Posts Q1 Loss of 4c/Share

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q1 EPS of ($0.04), $0.06 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $10.29 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Bernstein SocGen Group Downgrades Bridgestone Corp. (5108:JP) (BRDCY) to Market Perform
• ITG (ITG) Tops Q2 EPS by 1c